Safety and pharmacokinetics
toxicities, TEAEs, infections, headache, AD
ADVERSE EVENTS, ADVERSE EVENT, INFECTIONS
Single doses of KT-474 up to 1,600 mg and 14 daily doses up to 200 mg administered in the fasted state were well tolerated in HVs, with no dose-limiting toxicities and no serious adverse events (SAEs). The most common adverse event (AE) observed with KT-474 in SAD and MAD was mild to moderate headache (Extended Data Tables The safety profile in patients with HS and patients with AD who were treated with 75 mg of KT-474 daily for 28 d administered in the fed state was similar to that in HVs, with no drug-related infections (Table TEAEs by preferred term in patients with HS or AD and totalTEAE, treatment-emergent adverse event.Plasma pharmacokinetics (PK) in HVs after a single dose of KT-474 showed dose-dependent exposure increases, plateauing after the 1,000-mg dose with a maximum concentration (CIn patients, steady-state plasma C